Abstract: This disclosure relates to the development of nucleotide compositions directed to spliced gene variants that generate circular RNAs that are indicative of Alzheimer's disease. In some aspects, the nucleotides are siRNA compositions. In some aspects, the circular RNA is from a backspliced variant produced from the MAPT gene. The circular RNAs contain multiple microtubule binding domains and feature no frame shift and no stop codon when translated, allowing for consistent production. The siRNA compositions disclosed herein demonstrate good efficacy at silencing expression of the circRNAs. Circular RNAs, including tau circular RNAs exhibit a dramatic increase in translation after undergoing A>I editing, i.e. deamination of adenosines to inosines, which causes the formation and accumulation of pathological proteins. This accumulation can be prevented by siRNAs. In addition, five circular RNAs have been identified that correlate in expression levels with Alzheimer's disease severity.

Abstract: The present disclosure concerns isolated double stranded (ds) silencing RNA (siRNA) to target a backsplice junction between exons 12 and 7 in the MAPT gene. The ds siRNA include at least one nucleotide from the 3? terminus of exon 12 linked to at least one nucleotide of the 5? terminus of exon 7, thereby overlapping the backsplice junction. Targeting the junction ensure that that ds siRNA are limited in targeting the circular RNA produced by the backsplicing while allowing normal expression of the MAPT gene.

Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.

Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.

Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.

Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.

Abstract: A loading flap is pivotally mounted on the backrest of a vehicle seat and can be locked with the backrest. The locking operation can be carried out using positive and/or non-positive means, e.g. a bolt that moves in a translatory and rotative manner during locking and unlocking. The loading flap includes a housing that may be moved in a translatory manner parallel thereto during opening.

Abstract: The invention relates to a loading flap which is pivotally mounted on the backrest of a vehicle seat and can be locked with said backrest. The locking operation can be carried out using positive and/or non-positive means, e.g. a bolt that moves in a translatory and rotative manner during locking and unlocking.

Abstract: The present inventions relates to substances which are capable of controlling the inclusion of exon (10) of the tau gene. The substances can reverse “wrong” tau splicing pattern and. Since “wrong” tau splicing patterns are associated with tauopathies that cause dementia, the substances can be used as therapeutic agents. The invention also provides a method for testing substances that control tau exon (10) inclusion. The method is suitable for a high throughput screening. Additional products which are useful for changing tau exon (10) expression or for performing the test method are described as well.